A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
Hepatocellular Carcinoma
DRUG: Casdozokitug|DRUG: Toripalimab|DRUG: Bevacizumab
Number of Participants with Treatment-emergent Adverse Events (TEAEs), From date of first dose to 90 days after date of last dose (Up to approximately 27 months)|Objective Response Rate (ORR) by Investigator Review According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Up to approximately 2 years
ORR by Investigator Review According to HCC Modified RECIST (mRECIST), Up to approximately 2 years|Duration of Response (DoR) by Investigator Review According to RECIST v1.1, Up to approximately 2 years|DoR by Investigator Review According to HCC mRECIST, Up to approximately 2 years|Progression-free Survival (PFS) by Investigator Review According to RECIST v1.1, Up to approximately 2 years|PFS by Investigator Review According to HCC mRECIST, Up to approximately 2 years|Disease Control Rate (DCR) by Investigator Review According to RECIST v1.1, Up to approximately 2 years|DCR by Investigator Review According to HCC mRECIST, Up to approximately 2 years|Overall Survival (OS), Up to approximately 2 years|Maximum Concentration (Cmax), Up to approximately 25 months|Minimum Concentration (Cmin), Up to approximately 25 months|Time to Cmax (Tmax), Up to approximately 25 months
The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.